A novel oral therapy that inhibits the interleukin-23 inflammatory pathway provided control of moderate-to-severe psoriasis ...

Please provide your email address to receive an email when new articles are posted on . Five factors were identified as reasons why patients avoid treatment with adalimumab and other biologics.

Hispanic adults with psoriasis receive biologics far less often than non-Hispanic White adults, despite having more prescriptions and more dermatologist visits.

Please provide your email address to receive an email when new articles are posted on . Biologic persistence in PsA depends on the whether the drug was a first or second therapy. Depression and ...

Therapeutic drug monitoring is associated with better treatment durability among children with inflammatory bowel diseases.

Biologic treatments are a new option for people with moderate to severe eczema or atopic dermatitis. Most people can control eczema with prevention techniques, topical treatments, or ultraviolet ...

The advent of novel biologics for the therapy of inflammatory bowel disease (IBD) has substantially increased the ability to induce and maintain remission of patients. With clinical response and ...

One biologic, adalimumab, is currently approved to treat hidradenitis suppurativa. Adalimumab works by targeting a specific inflammation pathway involved in the condition. Hidradenitis suppurativa (HS ...